TransMedics Group, Inc. TMDX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 41.15% | 20.70% | 21.18% | 32.18% | 32.24% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 41.15% | 20.70% | 21.18% | 32.18% | 32.24% |
| Cost of Revenue | 42.36% | 26.27% | 31.57% | 35.76% | 23.65% |
| Gross Profit | 40.30% | 17.20% | 14.66% | 29.72% | 39.00% |
| SG&A Expenses | 33.29% | 31.17% | 44.38% | 9.67% | 7.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.09% | 37.59% | 38.37% | 23.47% | 14.96% |
| Operating Income | 20.78% | -35.09% | -51.55% | 146.10% | 493.93% |
| Income Before Tax | 4.65% | -46.37% | -68.19% | 209.53% | 442.54% |
| Income Tax Expenses | 645.65% | 270.43% | 17.71% | -63,546.97% | -4,541.38% |
| Earnings from Continuing Operations | -29.80% | -57.94% | -71.52% | 1,436.87% | 476.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.80% | -57.94% | -71.52% | 1,436.87% | 476.83% |
| EBIT | 20.78% | -35.09% | -51.55% | 146.10% | 493.93% |
| EBITDA | 27.67% | -22.66% | -27.16% | 97.16% | 226.91% |
| EPS Basic | -30.97% | -58.75% | -72.07% | 1,408.82% | 465.34% |
| Normalized Basic EPS | 2.89% | -47.41% | -68.81% | 203.92% | 432.16% |
| EPS Diluted | -29.84% | -55.84% | -71.52% | 1,188.05% | 450.08% |
| Normalized Diluted EPS | 4.42% | -46.57% | -64.93% | 166.24% | 374.87% |
| Average Basic Shares Outstanding | 1.70% | 1.97% | 1.96% | 1.87% | 2.01% |
| Average Diluted Shares Outstanding | 0.21% | 0.37% | -9.32% | 16.24% | 14.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |